CYP2D6 and nervousness: To the best of our knowledge, this large (> 250,000 cases) population-based pharmacoepidemiological study is the first investigating clinical consequences of DDIs between newly initiated Central Nervous System (CNS) active drugs and CYP2D6-inhibiting drugs.